The above studies suggest that the modulation of ferroptosis, as shown with sulfasalazine (52), by targeting SLC7A11 among other strategies can be exploited as adjunct therapeutic targets for RA. This evidence concerns the gene SLC7A11 and rheumatoid arthritis.